Content :
Central Nervous System
Products organised per phase
| Phase |
Product |
Product |
Product |
Product |
Product |
| Approved / Launched / LCM |
STILNOX®/
AMBIEN®/MYSLEE®
zolpidem
Insomnia
|
AMBIEN CR®
zolpidem MR
Controlled Release
Insomnia, US;
Long-term use, US
|
- |
- |
- |
| Submitted |
- |
- |
- |
- |
- |
| Phase III |
teriflunomide
(HMR1726)
Immunomodulator
Multiple sclerosis
(monotherapy)
|
eplivanserin
(SR46349)
5-HT2A antagonist
Insomnia
|
saredutant
(SR48968)
NK2 antagonist
Depression; Anxiety
|
amibegron
(SR58611)
Beta3 agonist
Depression
|
volinanserin
(M100907)
5-HT2A antagonist
Insomnia
|
| Phase III |
zolpidem MR
Controlled Release
Insomnia, Japan
|
- |
- |
- |
- |
| Phase IIb |
nerispirdine
(HP184)
K+/Na+ channel
blocker
Multiple Sclerosis
|
AVE1625*
CB1 antagonist
Schizophrenia
|
teriflunomide
(HMR1726)
Immunomodulator
Multiple sclerosis (adjunct.
therapy)
|
surinabant
(SR147778)
CB1 antagonist
Smoking cessation
|
SSR149415
V1B antagonist
Depression; Anxiety
|
| Phase IIa |
SSR180575
PBR ligand
Diabetic Polyneuropathies
|
- |
- |
- |
- |
| Phase I |
AVE8112
PDE IV inhibitor
Alzheimer's
|
SAR102779
NK2 antagonist
backup saredutant
Depression; IBS
|
SSR103800
GLYT1 inhibitor
Schizophrenia
|
SSR125543
CRF1 antagonist
Depression; Anxiety
|
SSR180711
alpha7 nicotinic partial agonist
Alzheimer's; Schizophrenia
|
| Phase I |
SSR411298
FAAH inhibitor
Depression; Anxiety
|
- |
- |
- |
- |
| Preclinical |
SAR110894
H3 antagonist
Alzheimer’s; Schizophrenia; Attention deficit
disorders;
|
SAR115740
TRPV1 antagonist
Chronic inflammatory and
neuropathic pain
|
SAR130479
alpha7 nicotinic partial agonist
Schizophrenia
|
SAR501788
PBR ligand
Sensory and motor neuron
degeneration
|
- |
R&D portfolio presented on February 12, 2008
Also in: * Metabolic Disorders
|
